SEARCH

SEARCH BY CITATION

References

  • 1
    Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 173345.
  • 2
    McQuillan GM, Coleman PJ, Kruszon-Moran D et al. Prevalence of hepatitis B virus infection in the United States: the National health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 1418.
  • 3
    Poterucha JJ, Wiesner RH. Liver transplantation and hepatitis B. Ann Intern Med 1997; 126: 8057.
  • 4
    Hadzyannis SJ, Bramou T, Alexopoulou A et al. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. In: HollingerFB, LemonSM, MargolisHS, eds. Viral Hepatitis and Liver Disease. Baltimore, MD: Williams & Wilkens, 1991: 6736.
  • 5
    Wang C, Deubner H, Shuhart M et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection. Hepatology 2005; 42: 573A.
  • 6
    Ngyuen MH, Trinh H, Garcia RT et al. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation. Hepatology 2005; 42: 593A.
  • 7
    Lai M, Hyatt B, Afdahl N. Role of liver biopsy in patients with normal ALT and high HBV DNA. Hepatology 2005; 42: 720A.
  • 8
    Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 16874.
  • 9
    Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biologic gradient of serum hepatitis B virus DNA. JAMA 2006; 295: 6573.
  • 10
    Keeffe EB, Dietrich DT, Han S-H et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 93662.
  • 11
    Lok AS, McMahon B. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 85761.
  • 12
    Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 47289.
  • 13
    EASL Jury. EASL International Consensus Conference of Hepatitis B. 13-14 September 2002: Geneva, Switzerland. Consensus statement. J Hepatol 2003; 39: S3S25.
  • 14
    Marcellin P, Chang T, Lim S et al. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients. J Hepatol 2005; 42: 31A.
  • 15
    Gish RG, Chang TT, De Man RA et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). Hepatology 2005; 42: 267A.
  • 16
    Lau G, Cooksley H, Ribeiro RM et al. Randomized, double blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg+ chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology 2004; 40: 272A.
  • 17
    Lau DT, Everhart L, Kleiner DE et al. Long-term follow up of patients with chronic hepatitis B treated with interferon alfa. Gastroeneterology 1997; 113: 16607.
  • 18
    Chang TT, Shiffman M, Tong M et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B. J Hepatol 2004; 40: 126A.
  • 19
    Gish RG, Martin P, Schiff ER et al. Entecavir leads to sustained response off-treatment in nucleoside-naïve HBeAg(+)patients who met on-treatment response endpoints at 48 weeks of therapy in phase 3 study ETV-022. Gastroenterology 2005; 128: A6923.
  • 20
    Homann C, Krogsgaard K, Pedersen C et al. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 1991; 4: 41620.
  • 21
    Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360: 19216.
  • 22
    Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label pilot study. Lancet 2001; 358: 71823.
  • 23
    Crockett SD, Keeffe EB. Natural history and treatment of patients coinfected with hepatitis B and hepatitis C viruses. Ann Clin Microbiol Antimicrob 2005; 4: 13.
  • 24
    Liu CJ, Chen PJ, Lai MY. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2002; 37: 56876.
  • 25
    Alter HJ, Esteban JI. The hepatitis C virus: from bench to bedside. In: YoungNS, GersonSL, HighKA, eds. Clinical Hematology. Philadelphia, PA: Elsevier, 2006: 100314.
  • 26
    National Institutes of Health Consensus Development program. Management of Hepatitis C: 2002. Available at: http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm. Accessed 1 June, 2007.
  • 27
    Foster GR. Past, present and future hepatitis C treatments. Semin Liver Dis 2004; 24(Suppl. 2): 97104.
  • 28
    Yee HS, Currie SL, Darling JM et al. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenetrol 2006; 101: 236078.
    Direct Link: